Release form, composition and packing

Eye drops 0.25% in the form of a clear solution, a colorless or yellowish, odorless.

1 ml of timolol gidromaleat 3.42 mg, including Timolol 2.5 mg.

Excipients: benzalkonium chloride (as preservative, 0.03 mg), povidone, disodium edetate dihydrate, sodium dihydrogen phosphate dihydrate, sodium monogidrofosfata dodekagidrat, water d / and.

Eye drops 0.5% as a clear solution, a colorless or yellowish, odorless.

1 ml of timolol gidromaleat 6.83 mg, including timolol 5 mg.

Excipients: benzalkonium chloride (as preservative, 0.03 mg), povidone, disodium edetate dihydrate, sodium dihydrogen phosphate dihydrate, sodium monogidrofosfata dodekagidrat, water d / and. 5 ml - vials of polyethylene (1) - packs cardboard.

Clinico-pharmacological group: antiglaucoma medication - beta-blocker.

Pharmacological action

Antiglaucoma drug from a group of nonselective beta-blockers. Has no intrinsic sympathomimetic and membrane stabilizing activity. When used topically as eye drops reduces both high and normal intraocular pressure by reducing the formation of the intraocular fluid. No effect on accommodation, refraction and pupil size.

Effect of the drug appears 20 minutes after instillation in the conjunctival sac. Maximum reduction of intraocular pressure (IOP) is reached after 1-2 h and persists for 24 hours


When topically applied timolol maleate marginally exposed to systemic absorption. After the instillation of eye drops Cmax timolol in the aqueous humor anterior chamber is achieved in 1-2 hours for the few falls into the systemic circulation by absorption through the vessels of the conjunctiva, the mucous membranes of the nose and the lachrymal canal. Pochkai displayed in the form of metabolites. In infants and young children Cmax timolol in plasma exceeds that in plasma of adults.

increased intraocular pressure (ocular hypertension);

open-angle glaucoma;

secondary glaucoma (including afakicheskaya);

angle-closure glaucoma (in combination with miotikami as an additional means for reducing IOP);

congenital glaucoma (for lack of effectiveness of other therapeutic measures).

Dosing regimen

Set individually, depending on the evidence and baseline intraocular pressure (IOP). The drug is instilled 1 drop 2 times / day in the conjunctival sac of the affected eye. After stabilization of IOP can decrease the dose to 1 drop of 1 times / day.

The drug is designed for prolonged use. The patient should be warned that a break in the use of the drug or change the dose can be carried out only on the advice of a doctor.

Side effect
On the part of the vision: irritation, redness of the conjunctiva, eyelid skin, burning and itchy eyes, lacrimation, photophobia, edema of the corneal epithelium, dot the surface keratopathy, corneal giposteziya, diplopia, ptosis, dry eyes. During fistuliziruyuschih antiglaucoma operations may develop retinal detachment in the postoperative period.
Cardio-vascular system: congestive heart failure, bradycardia, decreased blood pressure, bradyarrhythmia, collapse, AV-block, cardiac arrest, transient ischemic attacks.
CNS and peripheral nervous system: headache, dizziness, weakness, depression, paresthesia.
With the respiratory system: dyspnea, bronchospasm, pulmonary insufficiency.
From the digestive system: nausea, diarrhea. Allergic reactions: eczema, urticaria. Other: rhinitis, sexual dysfunction, alopecia. Local application of newborns can lead to sleep apnea.

Allergic reaction with generalized skin rash;
chronic obstructive airways disease (including asthma);
severe heart failure;
sinus bradycardia;
AV-block II or III degree;
cardiogenic shock;
corneal dystrophy;
severe atrophic rhinitis;
Hypersensitivity to timolol.

With careful use of the drug in patients with hyperthyroidism, chronic bronchitis and emphysema. Patients with diabetes mellitus receiving insulin or oral hypoglycemic agents, the use of timolol may cause hypoglycemia.

Pregnancy and lactation

Application Arytimola during pregnancy and lactation (breastfeeding) is possible only when the intended benefits to the mother outweighs the potential risk to the fetus or infant. Enough experience on the drug in these periods is not, however, found that timolol crosses the placental barrier.

If the drug was used immediately before childbirth or during breastfeeding, the newborn must be monitored carefully for a few days after birth and throughout the treatment period, lactating mothers drug Arytimol.


The patient should be warned of the need to regularly visit a physician for the measurement of IOP and examination of the cornea. If the patient wears soft contact lenses, then he should not use the drug Arytimol because preservative may defer to the soft contact lenses and have an adverse effect on eye tissues.

Should remove the hard contact lenses before instillation of the drug, and install them again after 15 minutes. When transferring patients on timolol treatment may require correction of refractive errors after effects caused by the previously applicable miotikami.

In the case of the upcoming surgery with general anesthesia to remove the drug for 48 h.

Effects on ability to drive vehicles and management mechanisms

Immediately after instillation of the drug may reduce visual acuity and slowing pishomotornyh reactions, which may reduce the ability of occupations potentially hazardous activities that require attention. This effect is enhanced by the simultaneous use of alcohol.


Symptoms: dizziness, headache, arrhythmia, bradycardia, bronchospasm, nausea, and vomiting.

Treatment: Rinse eyes with water or saline, if necessary, symptomatic treatment.

Drug Interactions

Sharing Arytimola with eye drops containing adrenaline (epinephrine) can cause mydriasis.

IOP increased while using eye drops containing adrenaline (epinephrine) and pilocarpine. Reduction of blood pressure and slowing heart rate may potentiate a joint application Arytimola with calcium channel blockers, reserpine, and beta-blockers.

The simultaneous use of insulin or oral hypoglycemic agents may cause hypoglycemia. Timolol increases the effects of muscle relaxants.

Conditions and terms of

List B. The drug should be kept in the dark and inaccessible to children at or above 25 ° C. Shelf life - 3 years. After opening a bottle of eye drops storage period - 6 weeks.